FRAMINGHAM, Mass. & BOSTON–(BUSINESS WIRE)–Variantyx (www.variantyx.com) today announced the integration of its clinical whole genome testing pipeline with FDNA’s (www.fdna.com) Face2Gene suite of applications. Using its proprietary Genomic Intelligence® platform, Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on comprehensive whole genome sequencing (WGS). Integration with Face2Gene technology now enables clinicians worldwide to send information about the phenotypes, syndromes, and genes that correlate with a patient’s facial and clinical analysis to Variantyx directly, speeding analysis and improving variant interpretation.
Genetic Research in Africa: An Interview with Dr. Aime Lumaka
Dr. Aime Lumaka, a distinguished geneticist from the Democratic Republic of Congo, is at the forefront of advancing genetic research across Africa. As a pivotal figure in the Deciphering Developmental Disorders in Africa (DDD-Africa) initiative and the Principal Investigator of the African Rare Diseases Initiative (ARDI), Dr Lumaka is leading efforts to evaluate clinical exome sequencing in […]
